Moreover, a ropivacaine, imiquimod and ICG co-loaded PF127 hydrogel (PFIRM) synergistically prime tumor-specific CD8+ T cells and facilitate their recognition of tumor cells, enhancing the PTT effect on tumor. The gene discussed is CD8A; the disease is neoplasm.